Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk, the Danish maker of Ozempic and Wegovy, announced Tuesday that it has asked the Food and Drug Administration to ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. To that end, it has amycretin in FDA phase 1 and CagriSema in phase-2 trials, which both show greater efficacy ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

its next-generation weight loss drug CagriSema; and a move to diversify into rare diseases, with several data readouts expected this year. In 2025, Novo Nordisk is guiding for annual sales growth ...